3 transcripts
LEGN
Earnings call transcript
NASDAQ
2024 Q2
9 Aug 24
multiple myeloma patients treated at Mayo Clinic with antibody drug conjugate, CAR-T and T-cell engagers targeting BCMA in the period of 2018 through 2023
LEGN
Earnings call transcript
NASDAQ
2024 Q1
13 May 24
for CARVYKTI through the end of 2029. The increases to our production capacity will help ensure we meet our target of annualized capacity of 10,000
LEGN
Earnings call transcript
NASDAQ
2023 Q4
11 Mar 24
through the end of 2025.
In order to serve more patients and meet our revenue targets, we have expanded our supply of lentiviral vectors
- Prev
- 1
- Next